<DOC>
	<DOCNO>NCT02526823</DOCNO>
	<brief_summary>Anthracyclines basic drug lymphoma treatment . However , dose accumulation relate cardiac toxicity limit clinical application , especially adriamycin . Adriamycin gradually replace epirubicin . Polyethylene glycol liposome doxorubicin ( PLD ) go tumor tissue tumor angiogenesis produce target kill effect tumor tissue . PLD potential advantage treatment malignant tumor , include lymphoma .</brief_summary>
	<brief_title>Clinical Application Polyethylene Glycol Liposome Doxorubicin ( PLD ) Primary Lymphoma</brief_title>
	<detailed_description>Lymphoma one rapidly grow malignant tumor world . It divide two major category ( Hodgkin 's lymphoma ( HL ) non Hodgkin 's lymphoma ( NHL ) . Anthracyclines basic drug lymphoma treatment . However , dose accumulation relate cardiac toxicity limit clinical application , especially adriamycin . Adriamycin gradually replace epirubicin malignant tumor treatment similar effect less toxic side effect . Polyethylene glycol liposome doxorubicin ( PLD ) liposome formulation doxorubicin . Methoxy Polyethylene Glycol ( MPEG ) contain liposome surface decrease peak plasma level free drug , extend drug circulation time blood reduce chance non-specific distribution normal tissue . PLD go tumor tissue tumor angiogenesis produce target kill effect tumor tissue . PLD potential advantage treatment malignant tumor . In lymphoma patient ' therapy , clinical application PLD expect new method . Therefore , investigator design randomize control clinical study aim compare efficacy safety PLD epirubicin primary B-NHL , peripheral T-cell lymphoma ( PTCL ) HL patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Primary BNHL , PTCL ( ALK+ anaplastic large cell lymphoma NK ( natural killer cell ) /T cell lymphoma exclude ) HL patient confirm histopathology ; 2 . Ages ≥18 year old , &lt; 80 year old ; 3 . ECOG ( Eastern Cooperative Oncology Group）score : 02 4 . At least one measurable lesion ; 5 . Expected survival time≥3 month ; 6 . Liver function : transaminase≤2.5× upper limit normal value，bilirubin≤1.5×upper limit normal value ; 7 . Renal function : serum creatinine 44133 mmol/L ; 8 . Routine blood test：WBC≥3.0×109/L，Neutrophils≥1.5×109/L，Hb≥100g/L，Platelet≥80×109/L； LVEF≥50 % ; 9 . New York Heart Association ( NYHA ) heart function classification III grade 10. sign informed consent . 1 . Patients severe complication severe infection ; 2 . Invasion central nervous system ; 3 . Patients severe heart disease history , include ventricular tachycardia ( VT ) , atrial fibrillation ( AF ) , heart block , myocardial infarction ( MI ) , congestive heart failure ( CHF ) , coronary heart disease patient need therapy ; 4. patient severe allergic constitution , allergic intolerant drug composition chemotherapy regimens ; malignant tumor past 5 year ; 5. patient receive doxorubicin therapy , total cumulative dose adriamycin 300 mg/m2 , total cumulative dose epirubicin 450 mg/m2 ; 6 . Patients participate clinical study ; 7 . Other patient suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>